

University of Massachusetts Medical School

eScholarship@UMMS

Open Access Articles

Open Access Publications by UMMS Authors

2017-11-16

Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer

Yue Wang

Huazhong University of Science and Technology

Et al.

Let us know how access to this document benefits you.

Follow this and additional works at: <https://escholarship.umassmed.edu/oapubs>



Part of the [Cancer Biology Commons](#), [Computational Biology Commons](#), [Genetic Phenomena Commons](#), [Molecular Genetics Commons](#), and the [Neoplasms Commons](#)

Repository Citation

Wang Y, Ung MH, Cantor SB, Cheng C. (2017). Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer. Open Access Articles. <https://doi.org/10.1038/s41598-017-16138-2>. Retrieved from <https://escholarship.umassmed.edu/oapubs/3307>

Creative Commons License



This work is licensed under a [Creative Commons Attribution 4.0 License](#).

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.

SCIENTIFIC REPORTS

OPEN

Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer

Yue Wang^{1,2}, Matthew H. Ung², Sharon Cantor³ & Chao Cheng^{2,4,5}

BRCAness has important implications in the management and treatment of patients with breast and ovarian cancer. In this study, we propose a computational framework to measure the BRCAness of breast and ovarian tumor samples based on their gene expression profiles. We define a characteristic profile for BRCAness by comparing gene expression differences between *BRCA1/2* mutant familial tumors and sporadic breast cancer tumors while adjusting for relevant clinical factors. With this BRCAness profile, our framework calculates sample-specific BRCA scores, which indicates homologous recombination (HR)-mediated DNA repair pathway activity of samples. We found that in sporadic breast cancer high BRCAness score is associated with aberrant copy number of HR genes rather than somatic mutation and other genomic features. Moreover, we observed significant correlations of BRCA score with genome instability and neoadjuvant chemotherapy. More importantly, BRCA score provides significant prognostic value in both breast and ovarian cancers after considering established clinical variables. In summary, the inferred BRCAness from our framework can be used as a robust biomarker for the prediction of prognosis and treatment response in breast and ovarian cancers.

Breast cancer is the most common type of cancer in female patients, with one out of eight women developing breast cancer in their lifetime¹. Many factors have been found to be associated with the increased risk of this disease including family history². Familial breast cancer represents a minor percentage of all breast cancer cases and can occur in patients with one or more closely related family members diagnosed with breast, ovarian, or related cancer^{2,3}. Approximately 25% of familial breast cancer cases may be attributed to germline mutations in two major breast cancer susceptibility genes, *BRCA1*⁴ and *BRCA2*⁵. Germline mutations in *BRCA1* and *BRCA2* genes exhibit high penetrance and confer a 60–80% and 40–85% lifetime risk of developing breast cancer, respectively⁶. In ovarian cancer, *BRCA1* and *BRCA2* germline mutations will confer a risk of 40–60% and 30%, respectively⁷. Other than germline mutations in these two genes, many other genetic mutations or variants can contribute to familial breast cancer including germline mutations with high (*e.g.*, *TP53* and *PTEN*) and low penetrance (*e.g.*, *ATM* and *BRIP1*), as well as low-penetrance genetic variants (*e.g.*, single-nucleotide polymorphisms (SNPs))⁸.

BRCA1 and *BRCA2* are essential regulators of the homologous recombination (HR) pathway that are involved in the repair of double-stranded DNA breaks^{9,10}. HR-dependent DNA repair restores damaged DNA sequences to its original state without introducing DNA mutations. When this pathway is inactivated, *e.g.*, as a result of *BRCA1/2* mutations, alternative DNA repair pathways such as non-homologous end joining (NHEJ) become the major pathways utilized for repairing double-strand DNA breaks. These alternative repair mechanisms are error-prone and lead to rapid accumulation of somatic mutations which increase the risk of carcinogenesis^{11,12}. Interestingly, somatic mutations in *BRCA1/2* are rarely observed in sporadic breast cancers^{13,14}. However, defects in HR-dependent DNA repair can arise through other mechanisms, resulting in a “BRCA-like” phenotype. For

¹School of Electronic Information and Communications at Huazhong University of Science and Technology, Wuhan, Hubei, 430074, China. ²Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth College, Hanover, NH, 03755, USA. ³Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA, 01605, USA. ⁴Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth College, Lebanon, NH, 03766, USA. ⁵Department of Biomedical Data Sciences, Geisel School of Medicine at Dartmouth College, Lebanon, NH, 03766, USA. Correspondence and requests for materials should be addressed to C.C. (email: Chao.Cheng@dartmouth.edu)

this reason, the concept of “BRCAness” has been introduced to describe this shared phenotype between sporadic cancers and familial cancers with *BRCA1/2* mutations^{15,16}.

BRCAness has important implications in the management and treatment of patients with sporadic breast and ovarian cancer^{15–18}. It has been shown that tumors with defects in the HR-dependent DNA repair pathway are hypersensitive to alkylating, platinum-based chemotherapies that generate DNA interstrand crosslinks and induce double-stranded DNA breaks during crosslink removal^{19,20}. However, tumors with deficient *BRCA1* activity are not sensitive to mitotic spindle poisons such as the taxanes and vincristine²¹. This is because that spindle disruption caused by these agents can induce apoptotic cell death in *BRCA*-proficient but not in *BRCA*-deficient tumors. It has been shown that downregulation of *BRCA1* gene expression in ovarian cancer cell lines increases their sensitivity to platinum treatment but leads to resistance to antimicrotubule agents^{22,23}. In addition, tumors with deficient *BRCA1/2* are also sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors as a result of synthetic lethality^{24,25}. In particular, PARP is involved in another DNA repair pathway called base excision repair (BER) that repair single-strand DNA breaks²⁶. Inhibition of PARP results in accumulation of DNA single-strand breaks, replication fork collapse and double-strand DNA repair that are lethal in tumors with deficient HR pathway.

The hallmarks of BRCAness are elevated genomic instability and deficient HR pathway activity. Accordingly, there are two strategies to determine the BRCAness of sporadic breast tumor samples. The first strategy is to classify *BRCA*-like and non-*BRCA*-like samples based on copy number variation (CNV) data. Classification models have been constructed by selecting genomic regions with differential CNV between familial (with *BRCA1/2* germline mutations) and sporadic breast cancer samples, and then applying these models to assess BRCAness in sporadic samples²⁷. These methods assume that there exist ‘hot’ genomic regions with recurrent CNV shared by the majority of *BRCA*-deficient familial and *BRCA*-like sporadic samples. However, this assumption may not hold when considering the high heterogeneity of sporadic tumors. The second strategy is to define gene signatures that characterize HR deficiency and apply them to identify HR-deficient sporadic tumor samples. Konstantinopoulos *et al.*²⁸ defined a BRCAness gene signature by comparing transcriptomic profiles between *BRCA1/2* mutant and sporadic ovarian tumor samples, and applied it to classify sporadic ovarian tumors. Their approach demonstrated that samples with high levels of BRCAness were associated with improved survival. A related approach involves generating BRCAness gene expression profiles from breast cancer cell line with RNA-mediated inactivation of HR pathway genes (*e.g. BRCA1, RAD51* and *BRIT1*)²⁹. However, our previous study using this approach showed that the resulting gene expression profiles from these knockdown cell line were more likely to reflect the reduced proliferation of cells rather than HR deficiency³⁰.

In this study, we propose a robust statistical framework to characterize a BRCAness gene expression profile to interrogate *BRCA* activity in sporadic breast cancer samples. The BRCAness profile is generated by comparing gene expression between *BRCA1/2* mutant familial tumors with sporadic breast tumors. In addition, this statistical model used to define the profile takes into account clinical factors that could explain differences in gene expression, thus effectively isolating the expression changes most likely to be induced by varying levels of BRCAness. This characteristic BRCAness profile utilizes all genes rather than a gene signature composed of a selected group of genes to achieve robust statistical performance. Application of this framework to The Cancer Genome Atlas (TCGA) breast cancer omics data revealed high heterogeneity of BRCAness mechanisms in sporadic breast cancer. Our results indicate that in sporadic breast cancer, copy number variation (CNV), especially deletions, contributes more to the inactivation of HR pathway compared to somatic mutations, DNA methylation, and expression changes in *BRCA*-like samples. Other than *BRCA1/2*, CNV in other HR genes play a more important role to reduce HR pathway activity in sporadic breast tumors. We also identified several other HR pathway genes with CNV associated with BRCAness, suggesting that other members of the axis may contribute more to HR pathway activity. Moreover, the inferred *BRCA* score is predictive of clinical outcomes of patients with breast cancer, providing a potential prognostic marker. In addition, this BRCAness profile, although being defined for breast cancer, is also applicable to ovarian cancer.

Results

Schematic overview of our study. Our computational framework starts by comparing familial breast tumors carrying either *BRCA1* or *BRCA2* mutations with sporadic cancer samples to generate a BRCAness characteristic profile (Fig. 1). This comparison adjusts for several clinical factors including age, grade, tumor size, estrogen receptor (ER) status, and Human Epidermal Growth Factor Receptor 2 (HER2) status to ensure that the BRCAness characteristic profile reflects *BRCA1/2* mutation status rather than differences in the distribution of these clinical variables across patients. Given a tumor gene expression dataset, this BRCAness profile calculates a sample-specific *BRCA* score for each individual patient in the dataset by using the BASE algorithm, which measures the similarity between a patient’s tumor expression profile and the BRCAness profile³¹. Patients with higher *BRCA* scores are more similar to have *BRCA1/2* germline mutations in terms of their expression profiles, and thereby more likely to have defective HR pathway activity.

Defining characteristic weight profiles that encode BRCAness. We utilized the data generated by Larsen *et al.*³² to define three BRCAness characteristic profiles (denoted as *BRCA1*-, *BRCA2*- and *BRCA1/2*-based profiles) by respectively comparing *BRCA1*-, *BRCA2*- or *BRCA1/2*-mutant (both *BRCA1* and *BRCA2*) familial samples with sporadic samples. In a BRCAness profile, each gene was assigned a weight based on the difference in expression it exhibits between *BRCA1/2*-mutated familial from sporadic breast cancer samples. Namely, genes with high weights were significantly up- or down-regulated in *BRCA1/2*-mutated samples after adjusting for several clinical variables that may be potential confounders. We selected 300 genes with the highest positive (up-regulated in *BRCA1/2*-mutant) and 300 genes with the highest negative (down-regulated in *BRCA1/2*-mutant) weights in the BRCAness profile and identified the enriched biological pathways. Our results




Figure 1. Overview of our computational framework. In short, we first compared the gene expression profiles between familial and sporadic breast tumors considering related clinical factors (e.g. age, grade, tumor size, ER status and Her2 status) to generate a BRCAness profile. Second, by integrating gene expressions of given breast cancer samples, we calculated sample-specific BRCA scores. The scores inferred the BRCAness of patients with the higher score the higher likelihood to be BRCAness. Then, we showed that the BRCA score classifies familial from sporadic breast tumors, correlates with genomic instability, predicts patients' survival and predicts chemotherapy response. Lastly, we further applied the BRCAness profile defined with breast cancer profiles to ovarian cancer. The corresponding BRCA scores also can classify familial from sporadic samples and predict prognosis.

indicate that cell cycle associated and DNA replication pathways are significantly enriched in the up-regulated genes (Supplementary Table S1). In addition, the same analyses were performed using top weighted genes in BRCAness profiles defined based on *BRCA1* versus sporadic and *BRCA2* versus sporadic profiles and obtained similar results. These results are consistent with the known functions of *BRCA1* and *BRCA2* (Supplementary Table S1).

Calculated BRCA score discriminates familial from sporadic breast tumors. We then examined whether BRCA score could distinguish familial breast cancer patients from sporadic patients. Because the Larsen *et al.* dataset³² was utilized to define three BRCAness characteristic profiles, we first compared their performance using this dataset. We calculated sample-specific BRCA scores for the 33 *BRCA1*-mutant familial samples, the 22 *BRCA2*-mutant familial samples, and the 128 sporadic samples using the *BRCA1*, *BRCA2* and the *BRCA1/2*-profiles, respectively (Fig. 2a). We found that *BRCA1*-mutant (Mann-Whitney Wilcoxon test $P = 6e-13$) and *BRCA2*-mutant (Mann-Whitney Wilcoxon test $P = 6e-4$) familial samples have significantly higher BRCA scores than sporadic samples when using all three BRCAness profiles (Fig. 2a). To further evaluate the predictive accuracy of the BRCA score, we trained a binary classification model to classify familial breast tumors from sporadic tumors (Fig. 2b). When using the *BRCA1*-based profile, the calculated BRCA scores could clearly discriminate familial *BRCA1*-mutant tumors from sporadic ones with an area under the curve (AUC) 0.901 (Fig. 2b, left). Similarly, the BRCA scores were able to distinguish familial *BRCA2*-mutant tumors from sporadic ones (AUC = 0.718), and all familial *BRCA1/2*-mutant tumors from sporadic ones (AUC = 0.828). Consistent observations were showed in the classifications utilizing the *BRCA2*-based (Fig. 2b, middle) and the *BRCA1/2*-based (Fig. 2b, right) BRCAness profiles. These results indicate that the calculated BRCA score can distinguish familial breast cancer patients from sporadic ones with high accuracy and can capture differences in the BRCAness phenotype. A high BRCA score implies high likelihood of carrying a *BRCA1/2* germline mutation and thus a more deficient HR pathway. Notably, the calculated BRCA scores using the *BRCA1/2*-based profile achieved the best classification accuracy when comparing familial breast tumors from sporadic ones (Fig. 2b, right, AUC = 0.861 for *BRCA1* vs. sporadic, ACU = 0.809 for *BRCA2* vs. sporadic and AUC = 0.84 for *BRCA1/2* vs. sporadic). Based on these results, we applied the BRCA scores calculated using the *BRCA1/2*-based profile for subsequent analyses.

Moreover, we utilized the GSE50567³³ dataset to further test the ability of the BRCA score to classify breast cancer patients. This dataset contained 12 *BRCA1*- and 1 *BRCA2*-mutated hereditary breast tumors, 8 BRCAx (non-*BRCA1/2* mutations, donated as non-BRCA) hereditary breast tumors, 14 sporadic breast cancer samples and 6 normal samples. However, we found that 5 sporadic and 1 BRCAx samples had methylated *BRCA1* promoters which could result in transcriptional silencing of *BRCA1*³⁴ and a reduction in HR pathway activity.




Figure 2. BRCA score classifies familial from sporadic breast cancer patients. **(a)** Boxplot for comparisons of BRCA scores in germline mutate-*BRCA1* (green box), germline mutate-*BRCA2* (tawny box) and sporadic (blue box) breast cancer samples using gene expression of germline mutate-*BRCA1* (left), germline mutate-*BRCA2* (middle), germline mutate-*BRCA1/2* (both *BRCA1* and *BRCA2*, right) as reference to compare with those of sporadic ones, respectively. Mann-Whitney Wilcoxon test P-values were calculated to show the differences of BRCA scores between germline mutate-*BRCA1* and sporadic breast cancer samples, germline mutate-*BRCA2* and sporadic breast cancer samples. **(b)** ROC curves for the accuracy of classifying familial from sporadic breast cancer patients using BRCA scores calculated by comparing gene expression of germline mutate-*BRCA1* (left), germline mutate-*BRCA2* (middle), germline mutate-*BRCA1/2* (right) as reference to sporadic ones, respectively. Black curve: comparison of patients with germline *BRCA1* mutations to sporadic ones. Magenta curve: comparison of patients with germline *BRCA2* mutations to sporadic ones. Cyan curve: comparison of patients with germline *BRCA1* and *BRCA2* mutations to sporadic ones. AUC scores were shown. The BRCA scores calculated based on germline *BRCA1/2* mutations achieved the best AUCs. **(c)** Boxplot for BRCA scores calculated by integrating BRCAness profile and gene expression profile offered by GSE50567 which contains profiles for familial *BRCA1* and *BRCA2* (BRCA), other familial with non-*BRCA* mutations, sporadic and normal breast cancer samples. Whitney Wilcoxon test P-values were listed. **(d)** Same with **(c)** but for GSE27830 which contains profiles for four familial breast cancer samples including *BRCA1*, *BRCA2*, *CHEK2* and other mutations (non-mutations of aforementioned genes). **(e)** Same with **(c)** but for GSE19177 which contains profiles for three groups of familial breast cancer samples including *BRCA1*, *BRCA2* and non-*BRCA1/2* mutations.

Therefore, we combined these 6 patients with the 12 *BRCA1*- and 1 *BRCA2*-mutated hereditary breast cancer patients into one group (donated as “BRCA”). The comparison of BRCA scores showed that patients in the BRCA group have higher BRCA scores than normal breast samples (Fig. 2c, Mann-Whitney Wilcoxon test $P = 6e-06$)

and sporadic tumors (Mann-Whitney Wilcoxon test $P = 0.04$). Moreover, patients carrying *BRCA* mutations had higher BRCA scores than the other familial tumors with non-*BRCA* mutations (Mann-Whitney Wilcoxon test $P = 7 \times 10^{-4}$). Furthermore, we observed similar results in two additional familial breast cancer datasets. The GSE27830^{35–37} dataset provided gene expression profiles for 155 familial primary breast cancer samples including 47 *BRCA1*-, 6 *BRCA2*-, 26 *CHEK2*-mutant samples and 76 samples without mutations in these three genes. Due to the limited number of *BRCA2*-mutant patients, we merged *BRCA1*- and *BRCA2*-mutant patients into one group. Based on the *BRCA1/2*-based profile, we calculated BRCA scores to patients in this dataset and found that patients with *BRCA1/2* mutations have significantly higher BRCA scores than those with *CHEK2* (Mann-Whitney Wilcoxon test $P = 2 \times 10^{-5}$) and other gene (Mann-Whitney Wilcoxon test $P = 6 \times 10^{-5}$) mutations (Fig. 2d). We found similar results in the GSE19177 dataset^{38,39} which contains expression profiles for 19 *BRCA1*, 30 *BRCA2* and 25 non-*BRCA1/2* mutation familial breast cancer samples (Fig. 2e). Again, patients with *BRCA1* mutations had higher BRCA scores than those with non-*BRCA1/2* mutations. These observations suggest that the calculated BRCA score is an effective classifier to distinguish familial breast tumors from sporadic tumors and to identify *BRCA1* or *BRCA2* mutated patients within familial breast cancer patients. The score is negatively correlated with the deficient HR pathway activity caused by *BRCA1* or *BRCA2* mutation.

Association of BRCA score with genomic features. Because BRCAness significantly correlates with genomic instability¹⁵, we extended our computational framework to TCGA breast cancer datasets to further examine the correlation of BRCA score with genomic features. First, we investigated the association between BRCA score and somatic mutations. By comparing the difference in BRCA score between mutated and non-mutated samples for each gene, we found that somatic mutation status of three genes, *TP53* (Mann-Whitney-Wilcoxon Test $P = 2 \times 10^{-30}$), *PIK3CA* (Mann-Whitney-Wilcoxon Test $P = 1 \times 10^{-16}$) and *CHD1* (Mann-Whitney-Wilcoxon Test $P = 2 \times 10^{-17}$), were significantly correlated with the BRCA score. Specifically, patients with higher BRCA scores were more likely to carry *TP53* mutations (Supplementary Fig. S1). In contrast, patients with lower BRCA scores were more likely to harbor mutated *PIK3CA* and *CHD1* (Supplementary Fig. S1). Then, we examined the overall association between BRCA score and CNV in breast cancer samples. According to TCGA CNV dataset, we divided genes into deletion ($CNV < 1.2$), normal and duplication ($CNV > 2.8$) groups. Ranking TCGA patients based on their BRCA scores, we found that high BRCA scores correlate with CNV (Supplementary Fig. S1). Last, by calculating the z scores across CpG sites for each patient, we found that BRCA scores are overall associated with DNA methylation (Supplementary Fig. S1).

Then, we compared the BRCA scores of TCGA breast cancer samples with their CNV burden and mutation burden, respectively. We observed that patients with a higher BRCA score had higher CNV burden (Fig. 3a, $r = 0.624$) and higher mutation burden (Fig. 3b, $r = 0.409$). These results imply that the BRCA scores are positively correlated with genomic instability. This might be because a high BRCA score indicates a defective HR DNA repair pathway which can result in a more abnormal genome. Since BRCA scores infer HR pathway activity, we next focused on 27 HR genes defined by the KEGG database⁴⁰ to reveal the correlation between BRCA score and their genomic features. First, we ranked TCGA breast cancer patients based on their BRCA scores in a decreasing order. Second, we compared differences in CNV, DNA methylation, and gene expression of the 27 HR genes between top ranked patients (top 1% to 20%) and low ranked patients (remaining patients) (See Methods). We observed that patients with higher BRCA scores exhibited significant copy number deletion ($CNV < 1.2$) of the 27 HR genes compared to those with lower scores (Fig. 3c). In contrast, we observed no significant changes in DNA methylation or gene expression of the 27 HR genes between top ranking and low ranking patients. These results suggest that CNV is the primary driver of HR pathway inactivation, while DNA methylation and gene expression play minor roles in determining pathway activity. Moreover, we compared the BRCA scores for patients with 27 HR genes copy number deletion ($CNV < 1.2$) to the rest patients. Higher BRCA scores were observed in patients with deletion compared to the others (Fig. 3d, Mann-Whitney-Wilcoxon Test $P = 9 \times 10^{-12}$). When only focusing on the two key pathway genes, *BRCA1* and *BRCA2*, we observed that copy number deleted patients have higher BRCA scores (Fig. 3d, Mann-Whitney-Wilcoxon Test $P = 7 \times 10^{-4}$). However, the p-value for comparison using *BRCA1* and *BRCA2* was lower than that using the 27 HR genes which suggests that the deletion of other HR pathway genes might contribute more to effect HR pathway activity (Fig. 3d). In addition to CNV, we observed consistent results when comparing somatic mutation status with BRCA score. Namely, patients with mutations in the 27 HR genes ($n = 68$) exhibited higher BRCA scores compared to patients without a mutation in either of the 27 HR genes (Fig. 3e, Mann-Whitney-Wilcoxon Test $P = 0.02$). Moreover, patients with mutated *BRCA1* or *BRCA2* ($n = 25$) exhibited higher BRCA scores compared to non-mutant samples (Fig. 3e, Mann-Whitney-Wilcoxon Test $P = 0.006$).

BRCA score predicts breast cancer patient prognosis. We next sought to evaluate whether the BRCA score could predict survival outcomes of breast cancer patients. First, we calculated the BRCA scores using our method for patients from the METABRIC cohort, which provides the most comprehensive breast cancer gene expression dataset that is accompanied by exhaustive clinical records for 1,992 primary breast cancer patients⁴¹. We next compared the association of BRCA scores with clinic pathological characteristics including grade and stage which are well-established clinical indicators of disease severity. Our results show that the calculated BRCA score was positively correlated with tumor grade, with higher grade tumors showing higher BRCA scores (Mann-Whitney U-test, $P = 3 \times 10^{-88}$; Fig. 4a). Likewise, we observed that patients with stage 2–4 tumors exhibited significantly higher BRCA scores compared to patients with stage 1 tumors (Mann-Whitney U-test, $P = 2 \times 10^{-5}$; Fig. 4b). These results indicate that BRCA score reflects the aggressiveness of tumors and can serve as an indicator of disease progression.

Moreover, we ranked the BRCA scores of patients from high to low and analyzed the distribution of patients based on several variables including *TP53* mutation, ER status, progesterone receptor (PR) status, HER2




Figure 3. BRCA score correlates with breast cancer genomic features. **(a)** Correlation between BRCA scores and CNV burden. Spearman correlation coefficient and corresponding P-value were listed. **(b)** Correlation between BRCA scores and log-10 transferred mutation burden. Spearman correlation coefficient and corresponding P-value were listed. **(c)** We ranked TCGA breast cancer patients based on their BRCA scores in a decreasing order. We then compared the difference between top ranked (from 1% to 20%) patients and the remaining according to CNV, DNA methylation and gene expression of the 27 HR genes. The differences were calculated through the Mann-Whitney-Wilcoxon Test. Negative log-10 transferred P-values were shown. **(d)** Boxplot for BRCA scores in patients with 27 HR genes deletions and scores in the rest patients. And Boxplot for BRCA scores in patients with only *BRCA1* and *BRCA2* deletions and scores in the rest patients. Mann-Whitney-Wilcoxon Test P-values were listed. **(e)** Boxplot for BRCA scores in patients with 27 HR genes mutations and scores in the rest patients. And Boxplot for BRCA scores in patients with only *BRCA1* and *BRCA2* mutations and scores in the rest patients. Mann-Whitney-Wilcoxon Test P-values were listed.




Figure 4. BRCA score predicts prognosis for breast cancer patients. **(a)** Boxplot for BRCA scores of patients in different grades. Mann–Whitney U-test P-value was listed. **(b)** Same as **(a)** but for different cancer stages. **(c)** Distribution of BRCA scores based on breast cancer subtypes. Then, we ranked the BRCA scores and showed the correlations with *TP53* mutation, ER status, PR status, Her2 status, triple negative breast cancer (TNBC) and molecular breast cancer subtypes. We compared BRCA scores in *TP53* mutation vs. *TP53* wild type, ER+ vs. ER−, PR+ vs. PR−, Her2+ vs. Her2−, TNBC vs. the other breast cancer samples, Basal-like vs. non-Basal-like, HER2-Enriched vs. non-HER2-Enriched, Luminal A vs. non-Luminal A, Luminal B vs. non-Luminal B and Normal vs. non-Normal patients. P-values were calculated using Mann–Whitney Wilcoxon test. **(d–g)** Kaplan–Meier plots for BRCA scores comparison of the **(d)** discovery, **(e)** validation datasets in the METABRIC dataset, **(f)** Ur-Rehman dataset, **(g)** Vijver dataset. Patients with low BRCA scores (green curve) had better survival than those with high BRCA scores (red curve). Hazard ratio (HR) and log-rank test P-value were shown.

status, triple negative status, and molecular subtype (Fig. 4c and Supplementary Fig. S2). Patients carrying *TP53* mutations were tended to have higher BRCA scores compared to those with wild-type *TP53* (Mann–Whitney Wilcoxon test $P=2e-12$) which is consistent with our result in the TCGA dataset. Moreover, we found that ER+ patients have a higher likelihood of lower BRCA scores compared to those with ER− (Mann–Whitney Wilcoxon test $P=2e-34$). Similar, PR+ patients had lower calculated BRCA scores than those with PR− (Mann–Whitney Wilcoxon test $P=9e-31$). In contrast, patients with HER2+ tended to have higher BRCA scores (Mann–Whitney Wilcoxon test $P=5e-12$). Moreover, triple negative breast cancer (TNBC) was more likely to be present in patients with high BRCA scores (Mann–Whitney Wilcoxon test $P=1e-28$). Furthermore, we compared the BRCA scores in patients with Basal, HER2-enriched, Luminal A, Luminal B, or Normal-like tumors. Patients with higher BRCA scores had higher risk to be predicted as Basal-like (Mann–Whitney Wilcoxon test $P=2e-40$), HER2-enriched (Mann–Whitney Wilcoxon test $P=3e-18$) and Luminal B (Mann–Whitney Wilcoxon test $P=9e-50$) breast cancers. However, patients with lower BRCA scores were more likely to be Luminal A (Mann–Whitney Wilcoxon test $P=8e-91$) and Normal-like (Mann–Whitney Wilcoxon test $P=4e-49$) breast cancer. Additionally, normal-like breast cancer patients tend to have the lowest BRCA scores.

After demonstrating that BRCA scores vary across samples with different clinical features, we evaluated whether BRCA scores could predict breast cancer prognosis. Using BRCA score as the independent variable, we performed survival analyses in the METABRIC discovery and validation datasets. Namely we divided patients

into high and low BRCAness categories by stratifying on median BRCA score. We observed that high BRCAness was associated with a significant increase in mortality risk in the discovery cohort (Fig. 4d, $P = 2 \times 10^{-6}$) with a hazard ratio (HR) of 1.83. Similarly, this result was reproduced in the METABRIC validation dataset (Fig. 4e, $P = 6 \times 10^{-7}$, HR = 1.92). In addition, we found that the BRCA score was predictive of prognosis in ER+ patients in both the discovery (HR = 1.63, $P = 0.001$) and validation (HR = 2.24, $P = 1 \times 10^{-6}$) datasets, with BRCA score being associated with increased mortality risk (Supplementary Fig. S3). In ER- patients, exhibited lower prognostic ability potentially due to high heterogeneity of ER- tumors⁴². Interestingly, we found that TNBC patients with high BRCA scores exhibited improved survival in the discovery dataset (Supplementary Fig. S4, HR = 2.21, $P = 0.008$).

To further evaluate the reproducibility of the BRCA score to predict survival, we applied the weight profiles to interrogate and perform survival analysis in two additional breast cancer datasets by Ur-Rehman *et al.*⁴³ and Vijver *et al.*⁴⁴. Our results remained consistent in that patients with high BRCA scores had worst prognosis than those with low BRCA scores (Ur-Rehman, Fig. 4f, $P = 2 \times 10^{-6}$, HR = 1.68; Vijver, Fig. 4g, $P = 2 \times 10^{-5}$, HR = 3.09). Additionally, the BRCA score was able to better predict mortality in patients with ER+ tumors compared to patients with ER- tumors in both datasets (Supplementary Fig. S4). Furthermore, to determine if the BRCA score could provide additional prognostic information to traditional clinicopathological variables, we fitted a multivariate Cox regression model to the METABRIC dataset using BRCA scores and clinical variables including age, ER status, Her2 status, stage, and grade as independent variables. Our results show that BRCA scores (HR = 1.63, $P = 3 \times 10^{-3}$) remain predictive to prognosis even after considering other clinical information (Supplementary Table S2).

BRCA score predicts patient response to neoadjuvant chemotherapy. Since BRCAness is a biomarker for responsiveness of chemotherapy¹⁵, we further examined whether the BRCA score could predict patient response to neoadjuvant chemotherapy. We calculated BRCA scores for patients in the Hatzis breast cancer dataset, which includes treatment response information to neoadjuvant taxane-anthracycline chemotherapy for 508 breast cancer samples⁴⁵. BRCA scores were calculated with the *BRCA1*-, *BRCA2*- and *BRCA1/2*-based profiles, respectively. First, we used BRCA scores to classify patients achieving pathologic complete response (pCR) and those with residual disease (RD). The results showed that using the *BRCA1*-based profile to calculate BRCA scores (AUC = 0.74) achieves the best accuracy for classification compared to using the *BRCA2*- (AUC = 0.59) or *BRCA1/2*-based (0.66) profiles (Fig. 5a). Moreover, to demonstrate that the BRCA score contributes to clinicopathological variables in predicting treatment response, we constructed random forest models to classify pCR patients from patients with RD (Fig. 5b). For one model, we only used the clinical variables including age, ER status, PR status, HER2 status, grade, stage, node information as predictors. We compared this model to a second model where we include both BRCA scores and clinicopathological variables as predictors. We observed that BRCA scores calculated from the *BRCA1*-based profile yielded the highest average AUC (AUC = 0.73) compared to scores generated from there *BRCA2*- (AUC = 0.715) and *BRCA1/2*-based (AUC = 0.719) profiles. These results suggest that using the BRCA scores calculated using *BRCA1*-based BRCAness profiles achieve the best accuracy for classification which in line with the previously studies^{46,47}. Therefore, we applied those *BRCA1*-based BRCA scores to the rest chemotherapy prediction.

Moreover, applying the BRCA scores calculated with *BRCA1*-based BRCAness profile, we found that pCR patients have higher BRCA scores than RD patients (Fig. 5c, Mann-Whitney-Wilcoxon Test $P = 3 \times 10^{-6}$). In addition, we observed consistent results in different breast cancer subtypes. For patients with ER+ (Mann-Whitney-Wilcoxon Test $P = 0.002$), ER- (Mann-Whitney-Wilcoxon Test $P = 0.002$) and TNBC (Mann-Whitney-Wilcoxon Test $P = 0.02$), we entirely found that pCR patients have higher BRCA scores compared to the RD patients (Supplementary Fig. S5). Moreover, we divided patients into low, intermediate, and high BRCA score groups and tested the fraction of pCR patients in each group. As shown in Fig. 5d, there were 5.9%, 14.7% and 35.3% pCR patients in these 3 groups. Moreover, patients with the high BRCA scores were 6-fold more likely to be pCR compared to those with the low scores. These observations suggest that our BRCA score could be utilized as a biomarker which can predict the response to neoadjuvant chemotherapy. Therefore, BRCA score could apply to practical clinical application helping doctors to improve treatment decisions and prognosis determinations.

Apply the BRCAness characteristic profile to ovarian cancer. Previous studies have shown that BRCAness also plays an important role in ovarian cancer^{48,49}. Briefly, due to the sensitivity of chemotherapy⁵⁰, BRCAness is significantly associated with ovarian cancer outcome⁵¹. Thus, we evaluated whether the BRCAness characteristic profile generated using breast cancer profiles can be applied to interrogate pathway activity in ovarian cancer. Using gene expression profiles from ovarian cancer tumor samples provided by Jazaeri *et al.*⁵², we first calculated sample-specific BRCA scores for each patient in the dataset using the *BRCA1/2*-based breast cancer profile. The Jazaeri dataset⁵² contained 18 germline *BRCA1* mutated, 16 germline *BRCA2* mutated and 27 sporadic ovarian cancer samples. By comparing the BRCA scores, we found that patients with *BRCA1* germline mutations have higher BRCA scores than either patients with *BRCA2* germline mutations (Fig. 6a, Mann-Whitney-Wilcoxon Test $P = 0.001$) or sporadic ones (Mann-Whitney-Wilcoxon Test $P = 7 \times 10^{-4}$) which are consistent with their results⁵². Moreover, using the BRCA score could classify *BRCA1*-mutated familial ovarian cancer tumors from sporadic ones with high accuracy (AUC = 0.778). When classifying *BRCA1* or *BRCA2* mutant samples from sporadic cancers we achieved an AUC = 0.660; however, classification of only germline *BRCA2* mutant tumors was inaccurate (AUC = 0.528) (Fig. 6b). These observations suggest that the BRCA score using the *BRCA1* profile can be applied as a prognostic biomarker in ovarian cancer.

Therefore, we tested whether the BRCA score could predict ovarian cancer prognosis using the Bonome *et al.*⁵³, TCGA⁵⁴ and the Yoshihara *et al.*⁵⁵ datasets, which contain 185, 557, and 260 patients, respectively. After




Figure 5. BRCA score predicts chemotherapy for breast cancer samples. (a) ROC curves for the accuracy of classifying pathologic complete response (pCR) from residual disease (RD) breast cancer patients. The BRCA scores were calculated using gene expression of germline mutate-*BRCA1* (red), germline mutate-*BRCA2* (blue), germline mutate-*BRCA1/2* (green) as reference to compare with those of sporadic ones, respectively. AUC scores were listed. (b) Barplot for the mean AUC scores of 10-fold cross validation using clinical information (gray), clinical information + *BRCA1* based BRCA scores (C+B1, red), clinical information + *BRCA2* based BRCA scores (C+B2, blue) and clinical information + *BRCA1/2* based BRCA scores (C+B1/2, green) to classify pCR from RD patients. The corresponding average AUCs were listed above each bar. Standard deviations were plotted with the error bars. (c) Boxplot for BRCA scores in patients with pCR (dark orange) and RD (chardonnay). BRCA scores were calculated using the *BRCA1*-based profiles. Mann-Whitney-Wilcoxon Test P-value was listed. (d) Barplot for pCR patients' fractions in different BRCA score groups. The chardonnay bar is RD patients and the dark orange bar is pCR patients. Corresponding pCR rate of each group were listed above the bars.

calculating a BRCA score for each patient, we divided them into BRCA-like and non BRCA-like groups using median BRCA score as the cutoff. Interestingly, we observed that BRCA-like patients exhibited decreased mortality risk in both the Bomone (Fig. 6c, HR = 0.67, $P = 0.03$) and TCGA datasets (Fig. 6d, HR = 0.68, $P = 9e-04$). A similar trend was observed using the Yoshihara dataset (Supplementary Fig. S6, HR = 0.9) but the difference between two groups was not significant ($P > 0.05$). These results were in line with the previous study^{28,56}, which suggest the BRCAness profile calculated with breast cancer expression profiles can be applied to ovarian cancer.




Figure 6. BRCA scores implements in ovarian cancer. (a) Boxplot for BRCA scores in germline mutate-*BRCA1*, germline mutate-*BRCA2* and sporadic ovarian cancer samples. Patients carrying germline *BRCA1* mutations had much higher BRCA scores than sporadic ones (Mann-Whitney-Wilcoxon Test $P = 7e-04$). (b) ROC curves for the accuracy of classifying familial from sporadic ovarian cancer patients using BRCA scores. Black curve: comparison of patients with germline *BRCA1* mutations to sporadic ones. Magenta curve: comparison of patients with germline *BRCA2* mutations to sporadic ones. Cyan curve: comparison of patients with germline *BRCA1* and *BRCA2* mutations to sporadic ones. AUC scores were shown. (c) Kaplan-Meier plots for patients' prognosis in the Bonome ovarian cancer dataset. BRCA-like patients (red curve) had better survival than non BRCA-like ones (green curve). Hazard ratio (HR) and log-rank test P-value were shown. (d) Same as (c) but for TCGA ovarian cancer samples.

Discussion

Our analyses indicate that BRCAness can be caused by different genomic mechanisms including somatic mutations, aberrant methylation, deletions and downregulated expression of genes involved in DNA repair. It is notable that gene deletions might contribute more to BRCAness than other genomic changes in sporadic breast cancers (Fig. 3a). In line with this observation, we found that the BRCA score of samples is more correlated with CNV burden than with mutation burden (Fig. 3b,c). However, this observation may not justify the use of CNV-based supervised classification models to assess BRCAness²⁷. Although BRCAness is associated with a high level of genome instability as manifested by high CNVs, genomic deletions or amplifications that occur may not exist in most BRCA-like samples to provide informative predictors for these classification models due to the heterogeneity of sporadic tumor samples—BRCAness can be caused by inactivating different genes via distinct mechanisms, such as DNA methylation and mutations. To address this shortcoming, we developed a framework that measures BRCAness based on transcriptomic profiles which capture the final downstream readout of genomic lesions that abrogate HR pathway activity. As such, a key question is why can the BRCAness profile be defined by comparing *BRCA1/2*-mutant familial tumor samples with sporadic samples? The familial breast tumor samples used for defining the BRCAness profile inherit a copy of defective *BRCA1/2* gene, predispose them to breast

cancer when the function of the other allele is lost (again, this can be caused by different genomic mechanisms). Thus, the familial breast tumor samples carrying *BRCA1/2* germline mutations represent a ‘homogenous’ set of cancers that are driven by HR pathway inactivation. As a result, it is possible to create a characteristic BRCAness gene expression profile that encodes the transcriptomic changes associated with known loss of HR pathway activity. Breast tumor’s HR pathway activity could be inferred via this profile where a high BRCA score that indicates low activity. Although the familial breast tumor samples provide an ideal positive dataset for defining BRCAness profile, the sporadic samples may not be a good negative dataset since some of these sporadic samples may be BRCA-like causing by other mechanisms such as *BRCA1* promoter DNA methylation, deletions of other HR genes or post-transcriptional regulation. Thus, we would expect to further improve our analysis by excluding these BRCA-like samples to achieve a more accurate BRCAness profile.

In the TCGA breast cancer data, 13 and 14 samples contain at least one somatic mutation in *BRCA1* and *BRCA2*, respectively. We mapped these mutations to the protein sequence of *BRCA1* and *BRCA2*, and calculated the corresponding BRCA scores for these samples (Supplementary Fig. S7). The majority of these patients with *BRCA1/2* somatic mutations are associated with positive BRCA scores, indicating lower HR pathway activities. However, nine out of 27 samples are associated with negative scores, suggesting that different mutation types in *BRCA1* and *BRCA2* genes vary in their functional impacts. To inactivate the HR pathway, both *BRCA1/2* alleles have to be defective, which might occur through different mechanisms. Furthermore, it is often difficult to determine the effect of a particular mutation occurred in *BRCA1/2* genes. Potentially, some mutated *BRCA1/2* proteins may preserve the ability to bind but cannot repair DNA, and furthermore, prevent the wild-type *BRCA1/2* (encoded by the other allele) from carrying out repairing functions, and therefore result in a dominant effect^{57,58} posing another layer of complexity. Therefore, the BRCA scores calculated by our framework provide a useful measurement for BRCAness in sporadic breast cancer samples.

Our analyses indicate that the BRCAness profile defined based on familial breast cancer samples can be applied to classify *BRCA1/2*-mutant familial versus sporadic ovarian cancer. It can also be used to assess BRCAness in sporadic ovarian tumor samples that show significant correlation with prognosis of patients. This indicates shared gene expression patterns between breast and ovarian cancer with BRCAness phenotypes. Interestingly, BRCAness is associated with poor prognosis in breast cancer but good prognosis in ovarian cancer. This might be due to the difference of treatments for these two cancer types. For ovarian cancers, it has higher likelihood to be high-grade serous carcinoma (HGSC) when the cancer was investigated⁵⁹. It has been confirmed that HGSC is sensitive to platinum-based chemotherapy⁶⁰. This is consistent with our conclusion that a patient with high BRCA score (high BRCA score is similar to HGSC) is more responsive to chemotherapy (Fig. 5c,d). In contrast, breast cancer is mostly driven by ER⁶¹ which is generally treated by hormone therapy.

Methods

Datasets. We collected gene expression and clinical information for breast cancer and ovarian cancer patients from 13 datasets (Supplementary Table S3). Larsen *et al.*³² provided the gene expression for 55 familial and 128 sporadic breast tumor samples. In the familial samples, 33 and 22 carry *BRCA1* and *BRCA2* germline mutations. We downloaded this data from the Gene Expression Omnibus (GEO) database with accession number GSE40115. The GSE50567³³ contained 12 *BRCA1*- and 1 *BRCA2*-mutated hereditary breast tumors, 8 BRCAx (non-*BRCA1/2* mutations) hereditary breast tumors, 14 sporadic breast cancer samples and 6 normal samples. The GSE27830^{35–37} dataset provided gene expression profiles for 155 familial primary breast cancer samples including 47 *BRCA1*-, 6 *BRCA2*-, 26 *CHEK2*- mutant samples and 76 samples without mutations in these three genes. The GSE19177 dataset^{38,39} contained expression profiles for 19 *BRCA1*, 30 *BRCA2* and 25 non-*BRCA1/2* mutation familial breast cancer samples. The METABRIC breast cancer dataset⁴¹ contained gene expression and exhaustive clinical profiles for 1,992 tumors which was downloaded from the European Genome Phenome Archive with accession number EGAS0000000083. The METABRIC dataset provided *TP53* status for 820 patients including 99 patients with *TP53* mutations and 721 patients with wild type *TP53*. The Ur-Rehman dataset⁴³ contained 1,170 samples integrated from 5 existed breast cancer datasets^{62–66} and was downloaded with accession number GSE47561. The Vijver dataset⁴⁴ was downloaded from the Netherlands Cancer Institute (<http://ccb.nki.nl/data/>) and contained gene expression and clinical profiles for 295 breast cancer patients. The Hatzis dataset⁴⁵ contained the response to neoadjuvant chemotherapy for 508 HER2-negative breast cancer samples with an accession ID GSE25066. Additionally, we applied our analyses to three OV datasets. Jazaeri dataset⁵² contained 18 germline mutated *BRCA1*, 16 germline mutated *BRCA2* and 27 sporadic ovarian cancer samples accessing with GSE82007. Bonome *et al.*⁵³ provided the gene expression profile for 185 late-stage and high-grade ovarian cancer patients with the accession number GSE26712. Yoshihara *et al.*⁵⁵ contained 260 Japanese advanced-stage ovarian cancer patients which was downloaded with an accession number GSE32062. Besides, additional TCGA datasets for breast cancer⁶⁷ and ovarian cancer⁵⁴ samples were collected from FIREHOSE Broad institute (<https://gdac.broadinstitute.org/>).

Define characteristic profiles for homologous recombination DNA repair pathway. The gene expression dataset generated by Larsen *et al.*³² was used to define the characteristic profile for BRCAness in breast cancer. This data was provided as log transformed expression at probeset level. We converted the data into gene expression data based on the probeset annotation. For genes with multiple probesets, the probeset with the highest average hybridization signals across all samples was selected to represent a gene.

Following that a logistic linear regression model was constructed for each gene to evaluate its power for differentiating *BRCA1/2*-mutant samples from sporadic samples while adjusting several important clinical variables. Specifically, the following model is used:

$$\ln(p_j/(1 - p_j)) = \alpha + \beta * \text{gene}_i + \gamma_1 * \text{age} + \gamma_2 * \text{grade} + \gamma_3 * \text{tumor size} \\ + \gamma_4 * \text{ER status} + \gamma_5 * \text{HER2 status},$$

where p_j is the probability of the sample j is *BRCA1/2*-mutant.

For each sample, the model calculated a coefficient and its p-value for each variable. The sign of β indicates whether *gene_i* has higher expression levels in familial (if $\beta > 0$) or sporadic (if $\beta \leq 0$) samples. The p-value for β indicates the capability of the gene to discriminate familial from sporadic samples, the smaller p-value the more significant discriminative power. Logistic linear regression was performed for all genes and the resulting beta coefficients were collected into a vector $B_j = \{\beta_1, \beta_2, \dots, \beta_n\}$ and the p-values were collected into a vector $P_j = \{p_1, p_2, \dots, p_n\}$, where n is the total number of genes. Based on the two vectors, a pair of weight profiles was generated to quantify the discriminative power of all genes to differentiate familial from sporadic samples using the following functions:

$$W_j^+ = -\log 10(p_i) * \mathbf{I}(\beta_i > 0) \text{ and } W_j^- = -\log 10(p_i) * \mathbf{I}(\beta_i \leq 0).$$

This pair of weight profiles characterize up- (W_j^+) and down-regulated (W_j^-) genes in j -th familial sample, respectively. \mathbf{I} is the indicator function which outputs 1 if $\beta > 0$ and 0 when $\beta \leq 0$. Weights greater than 10 in these profiles were trimmed to avoid extreme values. By integrating the weight profiles cross samples, we generated W^+ and W^- weight profiles, which, together, defines the characteristic profile for BRCAness. Based on the Larsen *et al.*³² dataset, we define three BRCAness profiles for breast cancer by comparing *BRCA1*, *BRCA2* and *BRCA1/2* familial samples with sporadic samples, respectively.

Calculate sample-specific activity score for homologous recombination DNA repair pathway.

The BRCAness profile weights genes in a sorted tumor gene expression profile to discriminate HR-defective samples (familial) from HR-proficient samples (sporadic). Given this profile, we apply a rank-based method to infer HR pathway activity in tumor samples based on their expression profiles. Typically, transcriptomic data for tumor samples are provided as either relative expression or absolute values dependent the platforms used for generating the data. When two channel microarray platforms are used, the resulting data represent relative expression of genes with respect to a reference sample. In contrast, one channel microarray and RNA-seq platforms generate absolute expression level of genes. In this case, we convert data into relative expression via median normalization.

Providing the relative gene expression profile for a tumor sample, we rank genes based on their expression and summarize the baseline expression of genes by referring to their weights in the BRCAness profile, resulting in a BRCA score which is a quantitative measure of HR pathway activity. The underlying rationale is that in BRCA-like samples highly expressed genes (*i.e.*, those with greater positive or negative relative expression values) tend to have higher weights in the BRCAness profile (W^+ and W^-), while the opposite is true for the non-BRCA-like samples. This form of correlation is nonlinear and is sensitive to genes distributed at the two ends of the sorted tumor gene expression profile. A rank-based statistical algorithm called BASE³¹, which is designed specifically to measure this correlation pattern, is applied to calculate BRCA scores in tumor samples. Briefly, genes are sorted into a ranked gene list based on their relative expression, and the biased distribution of BRCAness-upregulated (with high values in W^+) and downregulated (with high values in W^-) genes in this list were examined to obtain two scores, BS^+ and BS^- , respectively. The BRCA score is defined as their difference, $BS^+ - BS^-$. A higher BRCA score indicates high likelihood of BRCAness and thereby lower HR pathway activity. Conversely, a lower BRCA score indicates less likelihood of BRCAness and thereby higher HR pathway activity. A similar statistical framework has been applied to integrate cancer gene expression data with gene knockdown profiles with detailed description available from Wang *et al.*³⁰. The calculated BRCA scores were highly consistent with each other using *BRCA1*-, *BRCA2*- and *BRCA1/2*-based BRCAness profiles in all datasets we applied in our analyses (Supplementary Fig. S8).

Pathway enrichment analysis. According to the weights in the BRCAness profiles generated by comparing familial versus sporadic breast cancer samples, we selected 300 genes with the highest positive weights as the genes up-regulated in familial tumors. Similarly, three hundred down-regulated genes in familial tumors were selected with the highest negative weights. Pathway enrichment analysis was performed based on the REACTOME database⁶⁸. Hypergeometric test was used to calculate the p-value. Adjusted p-value was calculated by Benjamini and Hochberg method. All analyses were performed in R.

Associate BRCA scores with patient prognosis in breast and ovarian cancer. We applied Kaplan-Meier method to compare the survival times of patients in different groups. A log-rank test P-value was calculated to estimate the difference. Median of BRCA scores was applied as a threshold to divide patients into low and high BRCA score groups. The Cox proportional regression model was used to evaluate the individual contribution of BRCA scores to predicting survival in addition to the other clinical variables including age, ER status, Her2 status, tumor stage and tumor grade. Survival analysis was performed with the R package “survival”.

Correlate BRCA scores with genomic features. Using the gene expression profiles of TCGA breast cancer samples, we calculated a BRCA score for each sample. Because of the calculated BRCA score infers HR pathway activity, we focused on the genomic features of 27 HR genes that explains the majority of the correlation between BRCA score and genomic features including CNV, DNA methylation, and gene expression. First, we ranked TCGA breast cancer patients based on their BRCA scores in decreasing order. For CNV and gene

expression, we compared the difference between that in top ranked (from 1% to 20%) patients and the remaining ones for each 27 HR genes. For DNA methylation profile, we first used the average beta value of CpGs in the promoter (from -2k to 2k of transcription start site) of a gene to represent this gene. Then, we compared the difference between that in top ranked (from 1% to 20%) patients and the remaining ones for each 27 HR genes. The Mann-Whitney-Wilcoxon Test was applied to calculate the difference. The calculations of CVN burden and mutation burden were same with our previously study³⁰.

Associate BRCA scores with patient responsiveness to neoadjuvant chemotherapy. We used random forest⁶⁹ models to predict pCR and RD patients in the Hatzis dataset. We only considered clinical variables such as age, ER status, PR status, HER2 status, tumor grade, tumor stage, node information as predictors in the one model. In the other models, we combined the BRCA scores calculated using *BRCA1*-, *BRCA2*- and *BRCA1/2*-based profiles with those clinical predictors. The accuracy of prediction was investigated by calculating the AUC scores with 10-fold cross validation. The average and standard deviation of AUC scores were calculated to show the accuracy. The R package “randomForest” was used to perform these analyses. Moreover, R function “quantile” was utilized to divide patients into three groups.

References

- McGuire, A. *et al.* Effects of age on the detection and management of breast cancer. *Cancers (Basel)* **7**(2), 908–29 (2015).
- Collaborative Group on Hormonal Factors in Breast, C. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. *Lancet* **358**(9291), 1389–99 (2001).
- Evans, D. G. *et al.* Familial breast cancer: summary of updated NICE guidance. *BMJ* **346**, f3829 (2013).
- Miki, Y. *et al.* A strong candidate for the breast and ovarian cancer susceptibility gene *BRCA1*. *Science* **266**(5182), 66–71 (1994).
- Wooster, R. *et al.* Localization of a breast cancer susceptibility gene, *BRCA2*, to chromosome 13q12–13. *Science* **265**(5181), 2088–90 (1994).
- Chen, S. *et al.* Characterization of *BRCA1* and *BRCA2* mutations in a large United States sample. *J Clin Oncol* **24**(6), 863–71 (2006).
- Antoniou, A. *et al.* Average risks of breast and ovarian cancer associated with *BRCA1* or *BRCA2* mutations detected in case Series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* **72**(5), 1117–30 (2003).
- Couch, F. J., Nathanson, K. L. & Offit, K. Two decades after *BRCA*: setting paradigms in personalized cancer care and prevention. *Science* **343**(6178), 1466–70 (2014).
- Cerbinskaite, A. *et al.* Defective homologous recombination in human cancers. *Cancer Treat Rev* **38**(2), 89–100 (2012).
- Stefansson, O. A. *et al.* Genomic profiling of breast tumours in relation to *BRCA* abnormalities and phenotypes. *Breast Cancer Res* **11**(4), R47 (2009).
- Lord, C. J. & Ashworth, A. The DNA damage response and cancer therapy. *Nature* **481**(7381), 287–94 (2012).
- Honrado, E. *et al.* Pathology and gene expression of hereditary breast tumors associated with *BRCA1*, *BRCA2* and *CHEK2* gene mutations. *Oncogene* **25**(43), 5837–45 (2006).
- Lancaster, J. M. *et al.* *BRCA2* mutations in primary breast and ovarian cancers. *Nat Genet* **13**(2), 238–40 (1996).
- Futreal, P. A. *et al.* *BRCA1* mutations in primary breast and ovarian carcinomas. *Science* **266**(5182), 120–2 (1994).
- Lord, C. J. & Ashworth, A. *BRCA*ness revisited. *Nat Rev Cancer* **16**(2), 110–20 (2016).
- Turner, N., Tutt, A. & Ashworth, A. Hallmarks of ‘*BRCA*ness’ in sporadic cancers. *Nat Rev Cancer* **4**(10), 814–9 (2004).
- Muggia, F. & Safra, T. ‘*BRCA*ness’ and its implications for platinum action in gynecologic cancer. *Anticancer Res* **34**(2), 551–6 (2014).
- Pothuri, B. *BRCA1*- and *BRCA2*-related mutations: therapeutic implications in ovarian cancer. *Ann Oncol* **24**(Suppl 8), viii22–viii27 (2013).
- Howlett, N. G. *et al.* Biallelic inactivation of *BRCA2* in Fanconi anemia. *Science* **297**(5581), 606–9 (2002).
- Kraakman-van der Zwet, M. *et al.* *Brca2* (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. *Mol Cell Biol* **22**(2), 669–79 (2002).
- Lafarge, S. *et al.* Inhibition of *BRCA1* leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. *Oncogene* **20**(45), 6597–606 (2001).
- Zhou, C., Smith, J. L. & Liu, J. Role of *BRCA1* in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective *BRCA1*. *Oncogene* **22**(16), 2396–404 (2003).
- Sylvain, V., Lafarge, S. & Bignon, Y. J. Dominant-negative activity of a *Brca1* truncation mutant: effects on proliferation, tumorigenicity *in vivo*, and chemosensitivity in a mouse ovarian cancer cell line. *Int J Oncol* **20**(4), 845–53 (2002).
- Farmer, H. *et al.* Targeting the DNA repair defect in *BRCA* mutant cells as a therapeutic strategy. *Nature* **434**(7035), 917–21 (2005).
- Bryant, H. E. *et al.* Specific killing of *BRCA2*-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* **434**(7035), 913–7 (2005).
- Underhill, C., Toulmonde, M. & Bonnefoi, H. A review of PARP inhibitors: from bench to bedside. *Ann Oncol* **22**(2), 268–79 (2011).
- Schouten, P. C. *et al.* Robust *BRCA1*-like classification of copy number profiles of samples repeated across different datasets and platforms. *Mol Oncol* **9**(7), 1274–86 (2015).
- Konstantinopoulos, P. A. *et al.* Gene expression profile of *BRCA*ness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. *J Clin Oncol* **28**(22), 3555–61 (2010).
- Peng, G. *et al.* Genome-wide transcriptome profiling of homologous recombination DNA repair. *Nat Commun* **5**, 3361 (2014).
- Wang, Y. *et al.* Application of RNAi-induced gene expression profiles for prognostic prediction in breast cancer. *Genome Med* **8**(1), 114 (2016).
- Cheng, C. *et al.* Inferring activity changes of transcription factors by binding association with sorted expression profiles. *BMC Bioinformatics* **8**, 452 (2007).
- Larsen, M. J. *et al.* Classifications within molecular subtypes enables identification of *BRCA1/BRCA2* mutation carriers by RNA tumor profiling. *PLoS One* **8**(5), e64268 (2013).
- Lisowska, K. M. *et al.* *BRCA1*-related gene signature in breast cancer: the role of ER status and molecular type. *Front Biosci (Elite Ed)* **3**, 125–36 (2011).
- Rice, J. C. *et al.* Methylation of the *BRCA1* promoter is associated with decreased *BRCA1* mRNA levels in clinical breast cancer specimens. *Carcinogenesis* **21**(9), 1761–5 (2000).
- Massink, M. P. *et al.* Genomic profiling of *CHEK2**1100delC-mutated breast carcinomas. *BMC Cancer* **15**, 877 (2015).
- Massink, M. P. *et al.* Proper genomic profiling of (*BRCA1*-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes. *Mol Oncol* **9**(4), 877–88 (2015).
- Nagel, J. H. *et al.* Gene expression profiling assigns *CHEK2* 1100delC breast cancers to the luminal intrinsic subtypes. *Breast Cancer Res Treat* **132**(2), 439–48 (2012).

38. Yan, M. *et al.* Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCA1, but not BRCA1 familial breast cancers. *Breast Cancer Res* **14**(2), R69 (2012).
39. Waddell, N. *et al.* Subtypes of familial breast tumours revealed by expression and copy number profiling. *Breast Cancer Res Treat* **123**(3), 661–77 (2010).
40. Kanehisa, M. *et al.* KEGG: new perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Res* **45**(D1), D353–D361 (2017).
41. Curtis, C. *et al.* The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* **486**(7403), 346–52 (2012).
42. Bauer, K. R. *et al.* Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. *Cancer* **109**(9), 1721–8 (2007).
43. Ur-Rehman, S. *et al.* ROCK: a resource for integrative breast cancer data analysis. *Breast Cancer Res Treat* **139**(3), 907–21 (2013).
44. van de Vijver, M. J. *et al.* A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med* **347**(25), 1999–2009 (2002).
45. Hatzis, C. *et al.* A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. *JAMA* **305**(18), 1873–81 (2011).
46. James, C. R. *et al.* BRCA1, a potential predictive biomarker in the treatment of breast cancer. *Oncologist* **12**(2), 142–50 (2007).
47. Kirova, Y. M. *et al.* Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. *Eur J Cancer* **41**(15), 2304–11 (2005).
48. Kim, G. *et al.* FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy. *Clin Cancer Res* **21**(19), 4257–61 (2015).
49. Rigakos, G. & Razis, E. BRCAness: finding the Achilles heel in ovarian cancer. *Oncologist* **17**(7), 956–62 (2012).
50. Audeh, M. W. *et al.* Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet* **376**(9737), 245–51 (2010).
51. Ledermann, J. *et al.* Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med* **366**(15), 1382–92 (2012).
52. Jazaeri, A. A. *et al.* Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. *J Natl Cancer Inst* **94**(13), 990–1000 (2002).
53. Bonome, T. *et al.* A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. *Cancer Res* **68**(13), 5478–86 (2008).
54. Cancer Genome Atlas Research, N. Integrated genomic analyses of ovarian carcinoma. *Nature* **474**(7353), 609–15 (2011).
55. Yoshihara, K. *et al.* High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. *Clin Cancer Res* **18**(5), 1374–85 (2012).
56. Cass, I. *et al.* Improved survival in women with BRCA-associated ovarian carcinoma. *Cancer* **97**(9), 2187–95 (2003).
57. Suzuki, T., Maher, J. & Yamamoto, M. Select heterozygous Keap1 mutations have a dominant-negative effect on wild-type Keap1 *in vivo*. *Cancer Res* **71**(5), 1700–9 (2011).
58. Baldeyron, C. *et al.* A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining. *Oncogene* **21**(9), 1401–10 (2002).
59. Matulonis, U. A. *et al.* Ovarian cancer. *Nat Rev Dis Primers* **2**, 16061 (2016).
60. Bookman, M. A. *et al.* Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. *J Clin Oncol* **27**(9), 1419–25 (2009).
61. Stierer, M. *et al.* Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. *Ann Surg* **218**(1), 13–21 (1993).
62. Schmidt, M. *et al.* The humoral immune system has a key prognostic impact in node-negative breast cancer. *Cancer Res* **68**(13), 5405–13 (2008).
63. Loi, S. *et al.* Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. *BMC Genomics* **9**, 239 (2008).
64. Desmedt, C. *et al.* Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. *Clin Cancer Res* **13**(11), 3207–14 (2007).
65. Pawitan, Y. *et al.* Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. *Breast Cancer Res* **7**(6), R953–64 (2005).
66. Wang, Y. *et al.* Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. *Lancet* **365**(9460), 671–9 (2005).
67. Atlas, N. Comprehensive molecular portraits of human breast tumours. *Nature* **490**(7418), 61–70 (2012). Cancer Genome.
68. Fabregat, A. *et al.* The Reactome pathway Knowledgebase. *Nucleic Acids Res* **44**(D1), D481–7 (2016).
69. Svetnik, V. *et al.* Random forest: a classification and regression tool for compound classification and QSAR modeling. *J Chem Inf Comput Sci* **43**(6), 1947–58 (2003).

Acknowledgements

This work was supported by the American Cancer Society Research Grant IRG-82-003-30 (to CC), the NIH Centers of Biomedical Research Excellence (COBRE) grant GM103534 (to CC) and the Dartmouth Clinical and Translational Science Institute, under award number UL1TR001086 (to CC) and KL2TR001088 (to CC) from the National Center for Advancing Translational Sciences, and Dartmouth College Norris Cotton Cancer Center Support Grant P30CA023108 (to CC).

Author Contributions

C.C. and Y.W. designed this study. Y.W. and M.U. collected the all datasets, with C.C. as the main coordinator. Y.W. conducted all the analyses. S.C. and Y.W. prepared all figures, with Y.W. as the main coordinator. Y.W. and C.C. wrote the manuscript. C.C. supervised the work. All authors reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-017-16138-2>.

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017